Drug intelligence / Profile preview

reuterin

Development stage
Preclinical
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

Reuterin is a naturally occurring, broad-spectrum antimicrobial compound produced by the probiotic bacterium *Limosilactobacillus reuteri* (formerly *Lactobacillus reuteri*) during the anaerobic fermentation of glycerol. It is not a single substance but a dynamic multi-component system consisting of 3-hydroxypropionaldehyde (3-HPA), its hydrate, its dimer, and acrolein. Reuterin exhibits potent inhibitory activity against a wide range of Gram-positive and Gram-negative bacteria, as well as yeasts, molds, and protozoa. Its mechanism of action involves inducing oxidative stress and inhibiting ribonucleotide reductase, which interferes with DNA synthesis. While primarily studied as a food preservative and a key factor in the probiotic benefits of *L. reuteri*, recent research has highlighted its potential anti-inflammatory and anti-cancer properties, particularly in colorectal cancer models where it may be delivered via engineered probiotic strains.

Other names
3-hydroxypropionaldehyde3-HPAbeta-hydroxypropionaldehyde
02

Targets

RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on reuterin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on reuterin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call